What if you are buying specific assets:- Human application of...

What if you are buying specific assets:

- Human application of the CSIRO hairpin RNAi IP
- Proprietary gene therapy IP (DNA cassettes, transgenic delivery, etc.)
5 x Alnylam InterfeRx licenses
1 x HIV stem cell therapeutic at CoH
1 x HIV T-cell therapeutic at CoH
- License to use CoH gene therapy IP
- 4.2% of Tacere
- License/Royalty deal over the TT-033 IP
- Preclinical development agreement for Hepatitis B with Biomics
- Reagents revenue from the application of expressed RNAi to the research process (Sigma Aldrich, Promega, etc.)

Single lines of the above could be worth $50m.

Finally, add in the possibility of some fundamental RNAi IP - like acknowledgement, in patent terms, that Benitec was "first in animal cell" to conceive of the therapeutic application of RNAi. This is being battled with the USPTO - but it is already acknowledged throughout the British commonwealth ...

I am not really fussed if no one offers us $1 per share - as long as we have the ability to justify such a price in terms of development/license/royalty income streams.